Commercially available humanized monoclonal antibodies target key cytokines of the allergic and eosinophilic pathways in asthma pathogenesis including immunoglobulin E (IgE), interleukin (IL)‐5 (IL‐5) and IL‐4/IL‐13. Here, IL5 is linked to asthma.